Business Context and Reporting Period
This Form 8-K is a current report filed by AgeX Therapeutics, Inc. (not Serina Therapeutics, Inc.) on March 2, 2021. The registrant is a Delaware corporation with principal executive offices in Alameda, California, and its common stock trades on the NYSE American under the symbol AGE. The filing is intended to disclose "Other Events" pursuant to Item 8.01.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report serves as a notification of a press release rather than a financial statement.
Material Changes
The filing references a press release dated March 2, 2021 (Exhibit 99.1) but does not summarize the specific content of that release within the body of this Form 8-K. Consequently, no material changes to financial position or operations are detailed in this specific text.
Guidance, Outlook, and Risks
The document includes a standard disclaimer regarding forward-looking statements, noting that actual results may differ materially from anticipated results due to various factors. It directs investors to the "Risk Factors" section of the company's periodic reports for details on contingencies and risks. No specific guidance or management commentary on future performance is included in this text.
Investor Verification Checklist
- Verify the content of the press release filed as Exhibit 99.1 to understand the specific event triggering this filing.
- Confirm the company name is AgeX Therapeutics, Inc. (AGE), as the input metadata incorrectly listed "Serina Therapeutics, Inc."
- Review the company's most recent 10-K or 10-Q for actual financial metrics, as this 8-K contains none.
- Check the "Risk Factors" in periodic reports for details on the uncertainties mentioned in the forward-looking statements.